“…After the initiation of molecular therapy, the number of patients with complete response (CR) by response evaluation criteria in solid tumors (RECIST) and modified RECIST (mRECIST) criteria in diagnostic imaging increased; in contrast, complete remission of HCC is rarely achieved by molecular therapy alone (36). Conversely, many long-term survivors, including those completely cured, have been reported in patients with initially unresectable HCC after molecular therapy followed by conversion surgery (25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41)(42)(43). Partial response (PR) or stable disease after molecular therapy is required for patients to undergo conversion surgery, but CR is not always required (31).…”